Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$60.1 million.

  • Immunome's Net Income towards Common Stockholders fell 1903.33% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 2575.32%. This contributed to the annual value of -$305.8 million for FY2024, which is 18631.35% down from last year.
  • Latest data reveals that Immunome reported Net Income towards Common Stockholders of -$60.1 million as of Q3 2025, which was down 1903.33% from -$46.5 million recorded in Q2 2025.
  • Immunome's 5-year Net Income towards Common Stockholders high stood at -$4.3 million for Q3 2023, and its period low was -$132.3 million during Q1 2024.
  • In the last 3 years, Immunome's Net Income towards Common Stockholders had a median value of -$46.5 million in 2025 and averaged -$51.3 million.
  • In the last 5 years, Immunome's Net Income towards Common Stockholders plummeted by 285904.72% in 2024 and then surged by 6626.13% in 2025.
  • Over the past 3 years, Immunome's Net Income towards Common Stockholders (Quarter) stood at -$92.6 million in 2023, then grew by 10.43% to -$83.0 million in 2024, then increased by 27.52% to -$60.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$60.1 million for Q3 2025, versus -$46.5 million for Q2 2025 and -$44.6 million for Q1 2025.